WCG, a clinical trials solutions provider, is launching an AI-powered program dubbed Activation Intelligence to help study sites accelerate clinical trial start-up.
In the first two months of use in early access, Activation Intelligence helped WCG's initial customers save more than 20 hours of manual review per study activation while maintaining transparency into the information itself, according to an Oct. 12 release.
The program will fall within WCG’s broader Study Intelligence Hub, which is aimed at applying purpose-built AI across study workflows to improve consistency, reduce re-work needs and keep teams aligned as trials evolve.
The new AI-powered solution will extract information once, validate it against source documentation and make it reusable across activation workflows, WCG explained. Activation Intelligence also comes equipped with an AI assistant that users can query for congruency checks across study data, and to help identify any issues that might delay trial activation.
“Activation Intelligence reflects our commitment to applying purpose-built AI to the operational challenges that make clinical research more complex than it needs to be,” said Sam Srivastava, CEO of WCG, in the release. “By giving research teams greater confidence in the information guiding activation, we can help them make better decisions and move studies forward more efficiently.”
In April 2026, WCG acquired tech company The Contract Network to improve alignment and decision-making across clinical trial initiation.
The move bolstered WCG’s ClinSphere platform, which uses AI to guide trial design, assess site feasibility and support enrollment. Under that deal, WCG will leverage The Contract Network’s ability to identify inconsistencies in study documents and predict problems before they arrive or cause delays in the trial process.
Others are also using AI to bolster clinical trial services and design. Clinical research company nPhase launched a clinical data management platform designed to help trial sponsors leverage study results with AI, deemed nPhase.ai, in September 2026. Icon also recently announced a multi-year collaboration with Anthropic to tap Claude’s AI capabilities to improve clinical site intelligence and study planning.